Olpasiran vs Zerlasiran

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: LPA gene / apolipoprotein(a) mRNA · full Atherosclerotic Cardiovascular Disease pipeline

Olpasiran

Developed by Amgen and partners

Phase 3 in Atherosclerotic Cardiovascular DiseaseRNAi (siRNA)
Partial signal

NCT04270760 · Phase 2 · completed

The study randomly assigned 281 participants to four olpasiran regimens or placebo, with participants and investigators blinded. All four olpasiran groups significantly reduced the primary endpoint, percentage change in Lp(a) at week 36, versus placebo (all adjusted p<0.001), but this biomarker endpoint provides more limited evidence than a clinical cardiovascular outcome.

Next expected readout: March 2028 · NCT05581303 (registry estimate)

Reported efficacy

Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36 (Baseline and Week 36): Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36 (Baseline and Week 36): Group 1: Olpasiran 10 mg Q12W -66.91% ± 1.78 vs Group 2: Olpasiran 75 mg Q12W -93.78% ± 1.78 vs Group 3: Olpasiran 225 mg Q12W -97.53% ± 1.82 vs Group 4: Olpasiran 225 mg Q24W -96.89% ± 1.85 vs Group 5: Placebo Q12W 3.60% ± 1.89; p=<0.001 (Group 1: Olpasiran 10 mg Q12W vs Group 5: Placebo Q12W), p=<0.001 (Group 2: Olpasiran 75 mg Q12W vs Group 5: Placebo Q12W), p=<0.001 (Group 3: Olpasiran 225 mg Q12W vs Group 5: Placebo Q12W), p=< 0.001 (Group 4: Olpasiran 225 mg Q24W vs Group 5: Placebo Q12W) (met)

Result source: NCT04270760

Zerlasiran

Developed by Silence Therapeutics

Phase 2 in Atherosclerotic Cardiovascular DiseaseRNAi (siRNA)
Partial signal

NCT05537571 · Phase 2 · completed

The trial randomized participants to three zerlasiran regimens or placebo and masked both participants and investigators, with 180 participants enrolled. The primary endpoint was met for all active regimens, with statistically significant reductions in lipoprotein(a) versus pooled placebo; however, because the primary endpoint was a surrogate biomarker rather than a clinical outcome, this evidence is rated moderate.

Reported efficacy

Time-averaged Percent Change In Lipoprotein(a) Molar Concentration From Baseline to Week 36: Time-averaged Percent Change In Lipoprotein(a) Molar Concentration From Baseline to Week 36 (Week 36): SLN360 300 mg Q16W -80.5% (Standard Error 1.99) | SLN360 300 mg Q24W -79.1% (Standard Error 1.94) | SLN360 450 mg Q24W -83.3% (Standard Error 1.92) vs Pooled Placebo 2.3% (Standard Error 1.88) (met)

Result source: NCT05537571

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointOlpasiranZerlasiran
LDL-C, % change-17.3% vs 10.1%−27.4 vs placebo225 mg Q12W · wk 48 · n 54NCT04270760
7 other results
  • -16.9% vs 10.1% 225 mg Q24W · wk 48 · n 53 · Phase 2 · secondary NCT04270760
  • -16.7% vs 6.2% 225 mg Q12W · wk 36 · n 54 · Phase 2 · secondary NCT04270760
  • -18.5% vs 6.2% 225 mg Q24W · wk 36 · n 53 · Phase 2 · secondary NCT04270760
  • -11.5% vs 10.1% 75 mg Q12W · wk 48 · n 57 · Phase 2 · secondary NCT04270760
  • -16.3% vs 6.2% 75 mg Q12W · wk 36 · n 57 · Phase 2 · secondary NCT04270760
  • -14.7% vs 10.1% 10 mg Q12W · wk 48 · n 57 · Phase 2 · secondary NCT04270760
  • -17.4% vs 6.2% 10 mg Q12W · wk 36 · n 57 · Phase 2 · secondary NCT04270760
-17% vs 8.9%−25.9 vs placebo450 mg Q24W · wk 48 · n 45NCT05537571
8 other results
  • -15.5% vs 9.6% 450 mg Q24W · wk 36 · n 45 · Phase 2 · secondary NCT05537571
  • -14.7% vs 9.3% 450 mg Q24W · wk 60 · n 45 · Phase 2 · secondary NCT05537571
  • -20.9% vs 8.9% 300 mg Q16W · wk 48 · n 42 · Phase 2 · secondary NCT05537571
  • -18.5% vs 8.9% 300 mg Q24W · wk 48 · n 44 · Phase 2 · secondary NCT05537571
  • -22.3% vs 9.6% 300 mg Q16W · wk 36 · n 42 · Phase 2 · secondary NCT05537571
  • -20.1% vs 9.6% 300 mg Q24W · wk 36 · n 44 · Phase 2 · secondary NCT05537571
  • -19.3% vs 9.3% 300 mg Q16W · wk 60 · n 42 · Phase 2 · secondary NCT05537571
  • -16.8% vs 9.3% 300 mg Q24W · wk 60 · n 44 · Phase 2 · secondary NCT05537571
Non-HDL-C, % change—Trial running · NCT07293260—Not reported
ApoB, % change-7.2% vs 12.3%−19.5 vs placebo225 mg Q12W · wk 48 · n 54NCT04270760
7 other results
  • -9.5% vs 12.3% 225 mg Q24W · wk 48 · n 53 · Phase 2 · secondary NCT04270760
  • -10.2% vs 7.4% 225 mg Q12W · wk 36 · n 54 · Phase 2 · secondary NCT04270760
  • -11.4% vs 7.4% 225 mg Q24W · wk 36 · n 53 · Phase 2 · secondary NCT04270760
  • -4.8% vs 12.3% 75 mg Q12W · wk 48 · n 57 · Phase 2 · secondary NCT04270760
  • -9.3% vs 7.4% 75 mg Q12W · wk 36 · n 57 · Phase 2 · secondary NCT04270760
  • -7.7% vs 12.3% 10 mg Q12W · wk 48 · n 57 · Phase 2 · secondary NCT04270760
  • -11.5% vs 7.4% 10 mg Q12W · wk 36 · n 57 · Phase 2 · secondary NCT04270760
-18% vs -4%−14 vs placebo450 mg Q24W · wk 48 · n 45NCT05537571
8 other results
  • -18.6% vs -3.6% 450 mg Q24W · wk 36 · n 45 · Phase 2 · secondary NCT05537571
  • -16.4% vs -3.8% 450 mg Q24W · wk 60 · n 45 · Phase 2 · secondary NCT05537571
  • -16.4% vs -4% 300 mg Q16W · wk 48 · n 42 · Phase 2 · secondary NCT05537571
  • -12.6% vs -4% 300 mg Q24W · wk 48 · n 44 · Phase 2 · secondary NCT05537571
  • -16.9% vs -3.6% 300 mg Q16W · wk 36 · n 42 · Phase 2 · secondary NCT05537571
  • -13.5% vs -3.6% 300 mg Q24W · wk 36 · n 44 · Phase 2 · secondary NCT05537571
  • -15% vs -3.8% 300 mg Q16W · wk 60 · n 42 · Phase 2 · secondary NCT05537571
  • -10.9% vs -3.8% 300 mg Q24W · wk 60 · n 44 · Phase 2 · secondary NCT05537571
Lp(a), % change-97.5% vs 3.6%−101.1 vs placebo225 mg Q12W · wk 36 · n 53NCT04270760
133 other results
  • -96.9% vs 3.6% 225 mg Q24W · wk 36 · n 53 · Phase 2 · primary NCT04270760
  • -93.8% vs 3.6% 75 mg Q12W · wk 36 · n 57 · Phase 2 · primary NCT04270760
  • -66.9% vs 3.6% 10 mg Q12W · wk 36 · n 57 · Phase 2 · primary NCT04270760
  • -97.3% vs 3.6% 225 mg Q12W · wk 48 · n 54 · Phase 2 · secondary NCT04270760
  • -82.4% vs 3.6% 225 mg Q24W · wk 48 · n 53 · Phase 2 · secondary NCT04270760
  • -92.5% vs 3.6% 75 mg Q12W · wk 48 · n 57 · Phase 2 · secondary NCT04270760
  • -64.9% vs 3.6% 10 mg Q12W · wk 48 · n 57 · Phase 2 · secondary NCT04270760
  • -66.0% vs -26.7% 675 mg · wk 48.14 · n 6 · Phase 1 · secondary NCT03626662
  • -72.3% vs -31.5% 675 mg · wk 44.14 · n 6 · Phase 1 · secondary NCT03626662
  • -56.5% vs -19.3% 675 mg · wk 52.14 · n 6 · Phase 1 · secondary NCT03626662
  • -75.2% vs -23.8% 675 mg · wk 40.14 · n 6 · Phase 1 · secondary NCT03626662
  • -80.2% vs -24.9% 675 mg · wk 36.14 · n 6 · Phase 1 · secondary NCT03626662
  • -86.7% vs -4.9% 675 mg · wk 32.14 · n 6 · Phase 1 · secondary NCT03626662
  • -93.4% vs -22.3% 675 mg · wk 26.14 · n 6 · Phase 1 · secondary NCT03626662
  • -95.8% vs -15.2% 675 mg · wk 22.14 · n 6 · Phase 1 · secondary NCT03626662
  • -98.0% vs 3.4% 675 mg · wk 16.14 · n 6 · Phase 1 · secondary NCT03626662
  • -98.8% vs 1.3% 675 mg · wk 12.14 · n 6 · Phase 1 · secondary NCT03626662
  • -99.0% vs 1.3% 675 mg · wk 8.14 · n 6 · Phase 1 · secondary NCT03626662
  • -98.5% vs -6.5% 675 mg · wk 6.14 · n 6 · Phase 1 · secondary NCT03626662
  • -95.9% vs -1.6% 675 mg · wk 4.14 · n 6 · Phase 1 · secondary NCT03626662
  • -81.2% vs -1.6% 675 mg · wk 2.14 · n 6 · Phase 1 · secondary NCT03626662
  • -53.1% vs 0.7% 675 mg · wk 1 · n 6 · Phase 1 · secondary NCT03626662
  • -30.3% vs 11.5% 675 mg · wk 0.57 · n 6 · Phase 1 · secondary NCT03626662
  • -16.0% vs 8.4% 675 mg · wk 0.29 · n 6 · Phase 1 · secondary NCT03626662
  • -52.1% vs -26.7% 225 mg · wk 48.14 · n 5 · Phase 1 · secondary NCT03626662
  • -59.6% vs -31.5% 225 mg · wk 44.14 · n 5 · Phase 1 · secondary NCT03626662
  • -46.3% vs -19.3% 225 mg · wk 52.14 · n 5 · Phase 1 · secondary NCT03626662
  • -64.7% vs -23.8% 225 mg · wk 40.14 · n 5 · Phase 1 · secondary NCT03626662
  • -76.6% vs -24.9% 225 mg · wk 36.14 · n 5 · Phase 1 · secondary NCT03626662
  • -81.9% vs -4.9% 225 mg · wk 32.14 · n 6 · Phase 1 · secondary NCT03626662
  • -73.7% vs -4.9% 225 mg · wk 32.14 · n 5 · Phase 1 · secondary NCT03626662
  • -85.4% vs -22.3% 225 mg · wk 26.14 · n 6 · Phase 1 · secondary NCT03626662
  • -85.4% vs -22.3% 225 mg · wk 26.14 · n 5 · Phase 1 · secondary NCT03626662
  • -88.4% vs -15.2% 225 mg · wk 22.14 · n 6 · Phase 1 · secondary NCT03626662
  • -89.2% vs -15.2% 225 mg · wk 22.14 · n 5 · Phase 1 · secondary NCT03626662
  • -93.9% vs 3.4% 225 mg · wk 16.14 · n 6 · Phase 1 · secondary NCT03626662
  • -96.4% vs 3.4% 225 mg · wk 16.14 · n 5 · Phase 1 · secondary NCT03626662
  • -95.5% vs 1.3% 225 mg · wk 12.14 · n 6 · Phase 1 · secondary NCT03626662
  • -98.3% vs 1.3% 225 mg · wk 12.14 · n 5 · Phase 1 · secondary NCT03626662
  • -96.3% vs -1.5% 225 mg · wk 10.14 · n 6 · Phase 1 · secondary NCT03626662
  • -96.7% vs 1.3% 225 mg · wk 8.14 · n 6 · Phase 1 · secondary NCT03626662
  • -98.5% vs 1.3% 225 mg · wk 8.14 · n 5 · Phase 1 · secondary NCT03626662
  • -96.4% vs -6.5% 225 mg · wk 6.14 · n 6 · Phase 1 · secondary NCT03626662
  • -98.2% vs -6.5% 225 mg · wk 6.14 · n 5 · Phase 1 · secondary NCT03626662
  • -92.1% vs -1.6% 225 mg · wk 4.14 · n 6 · Phase 1 · secondary NCT03626662
  • -95.4% vs -1.6% 225 mg · wk 4.14 · n 5 · Phase 1 · secondary NCT03626662
  • -87.1% vs -3.1% 225 mg · wk 3.14 · n 6 · Phase 1 · secondary NCT03626662
  • -84.1% vs -6.0% 225 mg · wk 2.57 · n 6 · Phase 1 · secondary NCT03626662
  • -69.1% vs -1.6% 225 mg · wk 2.14 · n 6 · Phase 1 · secondary NCT03626662
  • -82.7% vs -1.6% 225 mg · wk 2.14 · n 5 · Phase 1 · secondary NCT03626662
  • -46.7% vs 0.7% 225 mg · wk 1 · n 6 · Phase 1 · secondary NCT03626662
  • -58.2% vs 0.7% 225 mg · wk 1 · n 5 · Phase 1 · secondary NCT03626662
  • -8.4% vs 11.5% 225 mg · wk 0.57 · n 6 · Phase 1 · secondary NCT03626662
  • -34.6% vs 11.5% 225 mg · wk 0.57 · n 5 · Phase 1 · secondary NCT03626662
  • -4.0% vs 8.4% 225 mg · wk 0.29 · n 6 · Phase 1 · secondary NCT03626662
  • -21.6% vs 8.4% 225 mg · wk 0.29 · n 5 · Phase 1 · secondary NCT03626662
  • -73.5% vs -4.9% 75 mg · wk 32.14 · n 6 · Phase 1 · secondary NCT03626662
  • -51.7% vs -4.9% 75 mg · wk 32.14 · n 9 · Phase 1 · secondary NCT03626662
  • -77.0% vs -22.3% 75 mg · wk 26.14 · n 6 · Phase 1 · secondary NCT03626662
  • -60.2% vs -22.3% 75 mg · wk 26.14 · n 9 · Phase 1 · secondary NCT03626662
  • -86.4% vs -15.2% 75 mg · wk 22.14 · n 6 · Phase 1 · secondary NCT03626662
  • -68.5% vs -15.2% 75 mg · wk 22.14 · n 9 · Phase 1 · secondary NCT03626662
  • -91.4% vs 3.4% 75 mg · wk 16.14 · n 6 · Phase 1 · secondary NCT03626662
  • -80.5% vs 3.4% 75 mg · wk 16.14 · n 9 · Phase 1 · secondary NCT03626662
  • -94.7% vs 1.3% 75 mg · wk 12.14 · n 6 · Phase 1 · secondary NCT03626662
  • -87.3% vs 1.3% 75 mg · wk 12.14 · n 9 · Phase 1 · secondary NCT03626662
  • -95.4% vs -1.5% 75 mg · wk 10.14 · n 6 · Phase 1 · secondary NCT03626662
  • -96.0% vs 1.3% 75 mg · wk 8.14 · n 6 · Phase 1 · secondary NCT03626662
  • -91.2% vs 1.3% 75 mg · wk 8.14 · n 9 · Phase 1 · secondary NCT03626662
  • -95.8% vs -6.5% 75 mg · wk 6.14 · n 6 · Phase 1 · secondary NCT03626662
  • -89.6% vs -6.5% 75 mg · wk 6.14 · n 9 · Phase 1 · secondary NCT03626662
  • -92.6% vs -1.6% 75 mg · wk 4.14 · n 6 · Phase 1 · secondary NCT03626662
  • -85.4% vs -1.6% 75 mg · wk 4.14 · n 9 · Phase 1 · secondary NCT03626662
  • -87.8% vs -3.1% 75 mg · wk 3.14 · n 6 · Phase 1 · secondary NCT03626662
  • -81.2% vs -6.0% 75 mg · wk 2.57 · n 6 · Phase 1 · secondary NCT03626662
  • -72.5% vs -1.6% 75 mg · wk 2.14 · n 6 · Phase 1 · secondary NCT03626662
  • -66.7% vs -1.6% 75 mg · wk 2.14 · n 9 · Phase 1 · secondary NCT03626662
  • -34.4% vs 0.7% 75 mg · wk 1 · n 6 · Phase 1 · secondary NCT03626662
  • -31.0% vs 0.7% 75 mg · wk 1 · n 9 · Phase 1 · secondary NCT03626662
  • -17.2% vs 11.5% 75 mg · wk 0.57 · n 6 · Phase 1 · secondary NCT03626662
  • -13.4% vs 11.5% 75 mg · wk 0.57 · n 9 · Phase 1 · secondary NCT03626662
  • 1.4% vs 8.4% 75 mg · wk 0.29 · n 6 · Phase 1 · secondary NCT03626662
  • -2.1% vs 8.4% 75 mg · wk 0.29 · n 9 · Phase 1 · secondary NCT03626662
  • -84.3% vs -4.9% 30 mg · wk 32.14 · n 6 · Phase 1 · secondary NCT03626662
  • -56.6% vs -15.2% 30 mg · wk 22.14 · n 6 · Phase 1 · secondary NCT03626662
  • -79.9% vs 3.4% 30 mg · wk 16.14 · n 6 · Phase 1 · secondary NCT03626662
  • -83.6% vs 1.3% 30 mg · wk 12.14 · n 6 · Phase 1 · secondary NCT03626662
  • -86.9% vs -1.5% 30 mg · wk 10.14 · n 6 · Phase 1 · secondary NCT03626662
  • -88.5% vs 1.3% 30 mg · wk 8.14 · n 6 · Phase 1 · secondary NCT03626662
  • -88.6% vs -6.5% 30 mg · wk 6.14 · n 6 · Phase 1 · secondary NCT03626662
  • -85.0% vs -1.6% 30 mg · wk 4.14 · n 6 · Phase 1 · secondary NCT03626662
  • -79.2% vs -3.1% 30 mg · wk 3.14 · n 6 · Phase 1 · secondary NCT03626662
  • -76.3% vs -6.0% 30 mg · wk 2.57 · n 6 · Phase 1 · secondary NCT03626662
  • -65% vs -1.6% 30 mg · wk 2.14 · n 6 · Phase 1 · secondary NCT03626662
  • -34.0% vs 0.7% 30 mg · wk 1 · n 6 · Phase 1 · secondary NCT03626662
  • 2.5% vs 11.5% 30 mg · wk 0.57 · n 6 · Phase 1 · secondary NCT03626662
  • 8.3% vs 8.4% 30 mg · wk 0.29 · n 6 · Phase 1 · secondary NCT03626662
  • -32.2% vs -4.9% 9 mg · wk 32.14 · n 9 · Phase 1 · secondary NCT03626662
  • -41.8% vs -22.3% 9 mg · wk 26.14 · n 9 · Phase 1 · secondary NCT03626662
  • -50.3% vs -15.2% 9 mg · wk 22.14 · n 9 · Phase 1 · secondary NCT03626662
  • -82.1% vs 3.4% 9 mg · wk 16.14 · n 6 · Phase 1 · secondary NCT03626662
  • -61.5% vs 3.4% 9 mg · wk 16.14 · n 9 · Phase 1 · secondary NCT03626662
  • -88.9% vs 1.3% 9 mg · wk 12.14 · n 6 · Phase 1 · secondary NCT03626662
  • -70.5% vs 1.3% 9 mg · wk 12.14 · n 9 · Phase 1 · secondary NCT03626662
  • -90.0% vs -1.5% 9 mg · wk 10.14 · n 6 · Phase 1 · secondary NCT03626662
  • -87.4% vs 1.3% 9 mg · wk 8.14 · n 6 · Phase 1 · secondary NCT03626662
  • -76.2% vs 1.3% 9 mg · wk 8.14 · n 9 · Phase 1 · secondary NCT03626662
  • -88.8% vs -6.5% 9 mg · wk 6.14 · n 6 · Phase 1 · secondary NCT03626662
  • -75.4% vs -6.5% 9 mg · wk 6.14 · n 9 · Phase 1 · secondary NCT03626662
  • -85.8% vs -1.6% 9 mg · wk 4.14 · n 6 · Phase 1 · secondary NCT03626662
  • -72.2% vs -1.6% 9 mg · wk 4.14 · n 9 · Phase 1 · secondary NCT03626662
  • -77.1% vs -3.1% 9 mg · wk 3.14 · n 6 · Phase 1 · secondary NCT03626662
  • -69.6% vs -6.0% 9 mg · wk 2.57 · n 6 · Phase 1 · secondary NCT03626662
  • -62.0% vs -1.6% 9 mg · wk 2.14 · n 6 · Phase 1 · secondary NCT03626662
  • -53.1% vs -1.6% 9 mg · wk 2.14 · n 9 · Phase 1 · secondary NCT03626662
  • -30.1% vs 0.7% 9 mg · wk 1 · n 6 · Phase 1 · secondary NCT03626662
  • -29.5% vs 0.7% 9 mg · wk 1 · n 9 · Phase 1 · secondary NCT03626662
  • -6.5% vs 11.5% 9 mg · wk 0.57 · n 6 · Phase 1 · secondary NCT03626662
  • -12.8% vs 11.5% 9 mg · wk 0.57 · n 9 · Phase 1 · secondary NCT03626662
  • -1.1% vs 8.4% 9 mg · wk 0.29 · n 6 · Phase 1 · secondary NCT03626662
  • -1.6% vs 8.4% 9 mg · wk 0.29 · n 9 · Phase 1 · secondary NCT03626662
  • -49.9% vs 3.4% 3 mg · wk 16.14 · n 6 · Phase 1 · secondary NCT03626662
  • -59.4% vs 1.3% 3 mg · wk 12.14 · n 6 · Phase 1 · secondary NCT03626662
  • -67.8% vs -1.5% 3 mg · wk 10.14 · n 6 · Phase 1 · secondary NCT03626662
  • -70.2% vs 1.3% 3 mg · wk 8.14 · n 6 · Phase 1 · secondary NCT03626662
  • -72.1% vs -6.5% 3 mg · wk 6.14 · n 6 · Phase 1 · secondary NCT03626662
  • -65.8% vs -1.6% 3 mg · wk 4.14 · n 6 · Phase 1 · secondary NCT03626662
  • -62.3% vs -3.1% 3 mg · wk 3.14 · n 6 · Phase 1 · secondary NCT03626662
  • -56.8% vs -6.0% 3 mg · wk 2.57 · n 6 · Phase 1 · secondary NCT03626662
  • -46.8% vs -1.6% 3 mg · wk 2.14 · n 6 · Phase 1 · secondary NCT03626662
  • -18.0% vs 0.7% 3 mg · wk 1 · n 6 · Phase 1 · secondary NCT03626662
  • -9.6% vs 11.5% 3 mg · wk 0.57 · n 6 · Phase 1 · secondary NCT03626662
  • -13.9% vs 8.4% 3 mg · wk 0.29 · n 6 · Phase 1 · secondary NCT03626662
-83.3% vs 2.3%−85.6 vs placebo450 mg Q24W · wk 36 · n 45NCT05537571
8 other results
  • -80.5% vs 2.3% 300 mg Q16W · wk 36 · n 42 · Phase 2 · primary NCT05537571
  • -79.1% vs 2.3% 300 mg Q24W · wk 36 · n 44 · Phase 2 · primary NCT05537571
  • -81.5% vs 1.5% 450 mg Q24W · wk 48 · n 45 · Phase 2 · secondary NCT05537571
  • -76% vs 1.1% 450 mg Q24W · wk 60 · n 45 · Phase 2 · secondary NCT05537571
  • -81.6% vs 1.5% 300 mg Q16W · wk 48 · n 42 · Phase 2 · secondary NCT05537571
  • -77.2% vs 1.5% 300 mg Q24W · wk 48 · n 44 · Phase 2 · secondary NCT05537571
  • -78% vs 1.1% 300 mg Q16W · wk 60 · n 42 · Phase 2 · secondary NCT05537571
  • -70.7% vs 1.1% 300 mg Q24W · wk 60 · n 44 · Phase 2 · secondary NCT05537571
3-point MACE (% with event)—Trial running · NCT07293260—Not reported

LDL-C, % change

Olpasiran
-17.3% vs 10.1%−27.4 vs placebo225 mg Q12W · wk 48 · n 54NCT04270760
7 other results
  • -16.9% vs 10.1% 225 mg Q24W · wk 48 · n 53 · Phase 2 · secondary NCT04270760
  • -16.7% vs 6.2% 225 mg Q12W · wk 36 · n 54 · Phase 2 · secondary NCT04270760
  • -18.5% vs 6.2% 225 mg Q24W · wk 36 · n 53 · Phase 2 · secondary NCT04270760
  • -11.5% vs 10.1% 75 mg Q12W · wk 48 · n 57 · Phase 2 · secondary NCT04270760
  • -16.3% vs 6.2% 75 mg Q12W · wk 36 · n 57 · Phase 2 · secondary NCT04270760
  • -14.7% vs 10.1% 10 mg Q12W · wk 48 · n 57 · Phase 2 · secondary NCT04270760
  • -17.4% vs 6.2% 10 mg Q12W · wk 36 · n 57 · Phase 2 · secondary NCT04270760
Zerlasiran
-17% vs 8.9%−25.9 vs placebo450 mg Q24W · wk 48 · n 45NCT05537571
8 other results
  • -15.5% vs 9.6% 450 mg Q24W · wk 36 · n 45 · Phase 2 · secondary NCT05537571
  • -14.7% vs 9.3% 450 mg Q24W · wk 60 · n 45 · Phase 2 · secondary NCT05537571
  • -20.9% vs 8.9% 300 mg Q16W · wk 48 · n 42 · Phase 2 · secondary NCT05537571
  • -18.5% vs 8.9% 300 mg Q24W · wk 48 · n 44 · Phase 2 · secondary NCT05537571
  • -22.3% vs 9.6% 300 mg Q16W · wk 36 · n 42 · Phase 2 · secondary NCT05537571
  • -20.1% vs 9.6% 300 mg Q24W · wk 36 · n 44 · Phase 2 · secondary NCT05537571
  • -19.3% vs 9.3% 300 mg Q16W · wk 60 · n 42 · Phase 2 · secondary NCT05537571
  • -16.8% vs 9.3% 300 mg Q24W · wk 60 · n 44 · Phase 2 · secondary NCT05537571

Non-HDL-C, % change

Olpasiran
—Trial running · NCT07293260
Zerlasiran
—Not reported

ApoB, % change

Olpasiran
-7.2% vs 12.3%−19.5 vs placebo225 mg Q12W · wk 48 · n 54NCT04270760
7 other results
  • -9.5% vs 12.3% 225 mg Q24W · wk 48 · n 53 · Phase 2 · secondary NCT04270760
  • -10.2% vs 7.4% 225 mg Q12W · wk 36 · n 54 · Phase 2 · secondary NCT04270760
  • -11.4% vs 7.4% 225 mg Q24W · wk 36 · n 53 · Phase 2 · secondary NCT04270760
  • -4.8% vs 12.3% 75 mg Q12W · wk 48 · n 57 · Phase 2 · secondary NCT04270760
  • -9.3% vs 7.4% 75 mg Q12W · wk 36 · n 57 · Phase 2 · secondary NCT04270760
  • -7.7% vs 12.3% 10 mg Q12W · wk 48 · n 57 · Phase 2 · secondary NCT04270760
  • -11.5% vs 7.4% 10 mg Q12W · wk 36 · n 57 · Phase 2 · secondary NCT04270760
Zerlasiran
-18% vs -4%−14 vs placebo450 mg Q24W · wk 48 · n 45NCT05537571
8 other results
  • -18.6% vs -3.6% 450 mg Q24W · wk 36 · n 45 · Phase 2 · secondary NCT05537571
  • -16.4% vs -3.8% 450 mg Q24W · wk 60 · n 45 · Phase 2 · secondary NCT05537571
  • -16.4% vs -4% 300 mg Q16W · wk 48 · n 42 · Phase 2 · secondary NCT05537571
  • -12.6% vs -4% 300 mg Q24W · wk 48 · n 44 · Phase 2 · secondary NCT05537571
  • -16.9% vs -3.6% 300 mg Q16W · wk 36 · n 42 · Phase 2 · secondary NCT05537571
  • -13.5% vs -3.6% 300 mg Q24W · wk 36 · n 44 · Phase 2 · secondary NCT05537571
  • -15% vs -3.8% 300 mg Q16W · wk 60 · n 42 · Phase 2 · secondary NCT05537571
  • -10.9% vs -3.8% 300 mg Q24W · wk 60 · n 44 · Phase 2 · secondary NCT05537571

Lp(a), % change

Olpasiran
-97.5% vs 3.6%−101.1 vs placebo225 mg Q12W · wk 36 · n 53NCT04270760
133 other results
  • -96.9% vs 3.6% 225 mg Q24W · wk 36 · n 53 · Phase 2 · primary NCT04270760
  • -93.8% vs 3.6% 75 mg Q12W · wk 36 · n 57 · Phase 2 · primary NCT04270760
  • -66.9% vs 3.6% 10 mg Q12W · wk 36 · n 57 · Phase 2 · primary NCT04270760
  • -97.3% vs 3.6% 225 mg Q12W · wk 48 · n 54 · Phase 2 · secondary NCT04270760
  • -82.4% vs 3.6% 225 mg Q24W · wk 48 · n 53 · Phase 2 · secondary NCT04270760
  • -92.5% vs 3.6% 75 mg Q12W · wk 48 · n 57 · Phase 2 · secondary NCT04270760
  • -64.9% vs 3.6% 10 mg Q12W · wk 48 · n 57 · Phase 2 · secondary NCT04270760
  • -66.0% vs -26.7% 675 mg · wk 48.14 · n 6 · Phase 1 · secondary NCT03626662
  • -72.3% vs -31.5% 675 mg · wk 44.14 · n 6 · Phase 1 · secondary NCT03626662
  • -56.5% vs -19.3% 675 mg · wk 52.14 · n 6 · Phase 1 · secondary NCT03626662
  • -75.2% vs -23.8% 675 mg · wk 40.14 · n 6 · Phase 1 · secondary NCT03626662
  • -80.2% vs -24.9% 675 mg · wk 36.14 · n 6 · Phase 1 · secondary NCT03626662
  • -86.7% vs -4.9% 675 mg · wk 32.14 · n 6 · Phase 1 · secondary NCT03626662
  • -93.4% vs -22.3% 675 mg · wk 26.14 · n 6 · Phase 1 · secondary NCT03626662
  • -95.8% vs -15.2% 675 mg · wk 22.14 · n 6 · Phase 1 · secondary NCT03626662
  • -98.0% vs 3.4% 675 mg · wk 16.14 · n 6 · Phase 1 · secondary NCT03626662
  • -98.8% vs 1.3% 675 mg · wk 12.14 · n 6 · Phase 1 · secondary NCT03626662
  • -99.0% vs 1.3% 675 mg · wk 8.14 · n 6 · Phase 1 · secondary NCT03626662
  • -98.5% vs -6.5% 675 mg · wk 6.14 · n 6 · Phase 1 · secondary NCT03626662
  • -95.9% vs -1.6% 675 mg · wk 4.14 · n 6 · Phase 1 · secondary NCT03626662
  • -81.2% vs -1.6% 675 mg · wk 2.14 · n 6 · Phase 1 · secondary NCT03626662
  • -53.1% vs 0.7% 675 mg · wk 1 · n 6 · Phase 1 · secondary NCT03626662
  • -30.3% vs 11.5% 675 mg · wk 0.57 · n 6 · Phase 1 · secondary NCT03626662
  • -16.0% vs 8.4% 675 mg · wk 0.29 · n 6 · Phase 1 · secondary NCT03626662
  • -52.1% vs -26.7% 225 mg · wk 48.14 · n 5 · Phase 1 · secondary NCT03626662
  • -59.6% vs -31.5% 225 mg · wk 44.14 · n 5 · Phase 1 · secondary NCT03626662
  • -46.3% vs -19.3% 225 mg · wk 52.14 · n 5 · Phase 1 · secondary NCT03626662
  • -64.7% vs -23.8% 225 mg · wk 40.14 · n 5 · Phase 1 · secondary NCT03626662
  • -76.6% vs -24.9% 225 mg · wk 36.14 · n 5 · Phase 1 · secondary NCT03626662
  • -81.9% vs -4.9% 225 mg · wk 32.14 · n 6 · Phase 1 · secondary NCT03626662
  • -73.7% vs -4.9% 225 mg · wk 32.14 · n 5 · Phase 1 · secondary NCT03626662
  • -85.4% vs -22.3% 225 mg · wk 26.14 · n 6 · Phase 1 · secondary NCT03626662
  • -85.4% vs -22.3% 225 mg · wk 26.14 · n 5 · Phase 1 · secondary NCT03626662
  • -88.4% vs -15.2% 225 mg · wk 22.14 · n 6 · Phase 1 · secondary NCT03626662
  • -89.2% vs -15.2% 225 mg · wk 22.14 · n 5 · Phase 1 · secondary NCT03626662
  • -93.9% vs 3.4% 225 mg · wk 16.14 · n 6 · Phase 1 · secondary NCT03626662
  • -96.4% vs 3.4% 225 mg · wk 16.14 · n 5 · Phase 1 · secondary NCT03626662
  • -95.5% vs 1.3% 225 mg · wk 12.14 · n 6 · Phase 1 · secondary NCT03626662
  • -98.3% vs 1.3% 225 mg · wk 12.14 · n 5 · Phase 1 · secondary NCT03626662
  • -96.3% vs -1.5% 225 mg · wk 10.14 · n 6 · Phase 1 · secondary NCT03626662
  • -96.7% vs 1.3% 225 mg · wk 8.14 · n 6 · Phase 1 · secondary NCT03626662
  • -98.5% vs 1.3% 225 mg · wk 8.14 · n 5 · Phase 1 · secondary NCT03626662
  • -96.4% vs -6.5% 225 mg · wk 6.14 · n 6 · Phase 1 · secondary NCT03626662
  • -98.2% vs -6.5% 225 mg · wk 6.14 · n 5 · Phase 1 · secondary NCT03626662
  • -92.1% vs -1.6% 225 mg · wk 4.14 · n 6 · Phase 1 · secondary NCT03626662
  • -95.4% vs -1.6% 225 mg · wk 4.14 · n 5 · Phase 1 · secondary NCT03626662
  • -87.1% vs -3.1% 225 mg · wk 3.14 · n 6 · Phase 1 · secondary NCT03626662
  • -84.1% vs -6.0% 225 mg · wk 2.57 · n 6 · Phase 1 · secondary NCT03626662
  • -69.1% vs -1.6% 225 mg · wk 2.14 · n 6 · Phase 1 · secondary NCT03626662
  • -82.7% vs -1.6% 225 mg · wk 2.14 · n 5 · Phase 1 · secondary NCT03626662
  • -46.7% vs 0.7% 225 mg · wk 1 · n 6 · Phase 1 · secondary NCT03626662
  • -58.2% vs 0.7% 225 mg · wk 1 · n 5 · Phase 1 · secondary NCT03626662
  • -8.4% vs 11.5% 225 mg · wk 0.57 · n 6 · Phase 1 · secondary NCT03626662
  • -34.6% vs 11.5% 225 mg · wk 0.57 · n 5 · Phase 1 · secondary NCT03626662
  • -4.0% vs 8.4% 225 mg · wk 0.29 · n 6 · Phase 1 · secondary NCT03626662
  • -21.6% vs 8.4% 225 mg · wk 0.29 · n 5 · Phase 1 · secondary NCT03626662
  • -73.5% vs -4.9% 75 mg · wk 32.14 · n 6 · Phase 1 · secondary NCT03626662
  • -51.7% vs -4.9% 75 mg · wk 32.14 · n 9 · Phase 1 · secondary NCT03626662
  • -77.0% vs -22.3% 75 mg · wk 26.14 · n 6 · Phase 1 · secondary NCT03626662
  • -60.2% vs -22.3% 75 mg · wk 26.14 · n 9 · Phase 1 · secondary NCT03626662
  • -86.4% vs -15.2% 75 mg · wk 22.14 · n 6 · Phase 1 · secondary NCT03626662
  • -68.5% vs -15.2% 75 mg · wk 22.14 · n 9 · Phase 1 · secondary NCT03626662
  • -91.4% vs 3.4% 75 mg · wk 16.14 · n 6 · Phase 1 · secondary NCT03626662
  • -80.5% vs 3.4% 75 mg · wk 16.14 · n 9 · Phase 1 · secondary NCT03626662
  • -94.7% vs 1.3% 75 mg · wk 12.14 · n 6 · Phase 1 · secondary NCT03626662
  • -87.3% vs 1.3% 75 mg · wk 12.14 · n 9 · Phase 1 · secondary NCT03626662
  • -95.4% vs -1.5% 75 mg · wk 10.14 · n 6 · Phase 1 · secondary NCT03626662
  • -96.0% vs 1.3% 75 mg · wk 8.14 · n 6 · Phase 1 · secondary NCT03626662
  • -91.2% vs 1.3% 75 mg · wk 8.14 · n 9 · Phase 1 · secondary NCT03626662
  • -95.8% vs -6.5% 75 mg · wk 6.14 · n 6 · Phase 1 · secondary NCT03626662
  • -89.6% vs -6.5% 75 mg · wk 6.14 · n 9 · Phase 1 · secondary NCT03626662
  • -92.6% vs -1.6% 75 mg · wk 4.14 · n 6 · Phase 1 · secondary NCT03626662
  • -85.4% vs -1.6% 75 mg · wk 4.14 · n 9 · Phase 1 · secondary NCT03626662
  • -87.8% vs -3.1% 75 mg · wk 3.14 · n 6 · Phase 1 · secondary NCT03626662
  • -81.2% vs -6.0% 75 mg · wk 2.57 · n 6 · Phase 1 · secondary NCT03626662
  • -72.5% vs -1.6% 75 mg · wk 2.14 · n 6 · Phase 1 · secondary NCT03626662
  • -66.7% vs -1.6% 75 mg · wk 2.14 · n 9 · Phase 1 · secondary NCT03626662
  • -34.4% vs 0.7% 75 mg · wk 1 · n 6 · Phase 1 · secondary NCT03626662
  • -31.0% vs 0.7% 75 mg · wk 1 · n 9 · Phase 1 · secondary NCT03626662
  • -17.2% vs 11.5% 75 mg · wk 0.57 · n 6 · Phase 1 · secondary NCT03626662
  • -13.4% vs 11.5% 75 mg · wk 0.57 · n 9 · Phase 1 · secondary NCT03626662
  • 1.4% vs 8.4% 75 mg · wk 0.29 · n 6 · Phase 1 · secondary NCT03626662
  • -2.1% vs 8.4% 75 mg · wk 0.29 · n 9 · Phase 1 · secondary NCT03626662
  • -84.3% vs -4.9% 30 mg · wk 32.14 · n 6 · Phase 1 · secondary NCT03626662
  • -56.6% vs -15.2% 30 mg · wk 22.14 · n 6 · Phase 1 · secondary NCT03626662
  • -79.9% vs 3.4% 30 mg · wk 16.14 · n 6 · Phase 1 · secondary NCT03626662
  • -83.6% vs 1.3% 30 mg · wk 12.14 · n 6 · Phase 1 · secondary NCT03626662
  • -86.9% vs -1.5% 30 mg · wk 10.14 · n 6 · Phase 1 · secondary NCT03626662
  • -88.5% vs 1.3% 30 mg · wk 8.14 · n 6 · Phase 1 · secondary NCT03626662
  • -88.6% vs -6.5% 30 mg · wk 6.14 · n 6 · Phase 1 · secondary NCT03626662
  • -85.0% vs -1.6% 30 mg · wk 4.14 · n 6 · Phase 1 · secondary NCT03626662
  • -79.2% vs -3.1% 30 mg · wk 3.14 · n 6 · Phase 1 · secondary NCT03626662
  • -76.3% vs -6.0% 30 mg · wk 2.57 · n 6 · Phase 1 · secondary NCT03626662
  • -65% vs -1.6% 30 mg · wk 2.14 · n 6 · Phase 1 · secondary NCT03626662
  • -34.0% vs 0.7% 30 mg · wk 1 · n 6 · Phase 1 · secondary NCT03626662
  • 2.5% vs 11.5% 30 mg · wk 0.57 · n 6 · Phase 1 · secondary NCT03626662
  • 8.3% vs 8.4% 30 mg · wk 0.29 · n 6 · Phase 1 · secondary NCT03626662
  • -32.2% vs -4.9% 9 mg · wk 32.14 · n 9 · Phase 1 · secondary NCT03626662
  • -41.8% vs -22.3% 9 mg · wk 26.14 · n 9 · Phase 1 · secondary NCT03626662
  • -50.3% vs -15.2% 9 mg · wk 22.14 · n 9 · Phase 1 · secondary NCT03626662
  • -82.1% vs 3.4% 9 mg · wk 16.14 · n 6 · Phase 1 · secondary NCT03626662
  • -61.5% vs 3.4% 9 mg · wk 16.14 · n 9 · Phase 1 · secondary NCT03626662
  • -88.9% vs 1.3% 9 mg · wk 12.14 · n 6 · Phase 1 · secondary NCT03626662
  • -70.5% vs 1.3% 9 mg · wk 12.14 · n 9 · Phase 1 · secondary NCT03626662
  • -90.0% vs -1.5% 9 mg · wk 10.14 · n 6 · Phase 1 · secondary NCT03626662
  • -87.4% vs 1.3% 9 mg · wk 8.14 · n 6 · Phase 1 · secondary NCT03626662
  • -76.2% vs 1.3% 9 mg · wk 8.14 · n 9 · Phase 1 · secondary NCT03626662
  • -88.8% vs -6.5% 9 mg · wk 6.14 · n 6 · Phase 1 · secondary NCT03626662
  • -75.4% vs -6.5% 9 mg · wk 6.14 · n 9 · Phase 1 · secondary NCT03626662
  • -85.8% vs -1.6% 9 mg · wk 4.14 · n 6 · Phase 1 · secondary NCT03626662
  • -72.2% vs -1.6% 9 mg · wk 4.14 · n 9 · Phase 1 · secondary NCT03626662
  • -77.1% vs -3.1% 9 mg · wk 3.14 · n 6 · Phase 1 · secondary NCT03626662
  • -69.6% vs -6.0% 9 mg · wk 2.57 · n 6 · Phase 1 · secondary NCT03626662
  • -62.0% vs -1.6% 9 mg · wk 2.14 · n 6 · Phase 1 · secondary NCT03626662
  • -53.1% vs -1.6% 9 mg · wk 2.14 · n 9 · Phase 1 · secondary NCT03626662
  • -30.1% vs 0.7% 9 mg · wk 1 · n 6 · Phase 1 · secondary NCT03626662
  • -29.5% vs 0.7% 9 mg · wk 1 · n 9 · Phase 1 · secondary NCT03626662
  • -6.5% vs 11.5% 9 mg · wk 0.57 · n 6 · Phase 1 · secondary NCT03626662
  • -12.8% vs 11.5% 9 mg · wk 0.57 · n 9 · Phase 1 · secondary NCT03626662
  • -1.1% vs 8.4% 9 mg · wk 0.29 · n 6 · Phase 1 · secondary NCT03626662
  • -1.6% vs 8.4% 9 mg · wk 0.29 · n 9 · Phase 1 · secondary NCT03626662
  • -49.9% vs 3.4% 3 mg · wk 16.14 · n 6 · Phase 1 · secondary NCT03626662
  • -59.4% vs 1.3% 3 mg · wk 12.14 · n 6 · Phase 1 · secondary NCT03626662
  • -67.8% vs -1.5% 3 mg · wk 10.14 · n 6 · Phase 1 · secondary NCT03626662
  • -70.2% vs 1.3% 3 mg · wk 8.14 · n 6 · Phase 1 · secondary NCT03626662
  • -72.1% vs -6.5% 3 mg · wk 6.14 · n 6 · Phase 1 · secondary NCT03626662
  • -65.8% vs -1.6% 3 mg · wk 4.14 · n 6 · Phase 1 · secondary NCT03626662
  • -62.3% vs -3.1% 3 mg · wk 3.14 · n 6 · Phase 1 · secondary NCT03626662
  • -56.8% vs -6.0% 3 mg · wk 2.57 · n 6 · Phase 1 · secondary NCT03626662
  • -46.8% vs -1.6% 3 mg · wk 2.14 · n 6 · Phase 1 · secondary NCT03626662
  • -18.0% vs 0.7% 3 mg · wk 1 · n 6 · Phase 1 · secondary NCT03626662
  • -9.6% vs 11.5% 3 mg · wk 0.57 · n 6 · Phase 1 · secondary NCT03626662
  • -13.9% vs 8.4% 3 mg · wk 0.29 · n 6 · Phase 1 · secondary NCT03626662
Zerlasiran
-83.3% vs 2.3%−85.6 vs placebo450 mg Q24W · wk 36 · n 45NCT05537571
8 other results
  • -80.5% vs 2.3% 300 mg Q16W · wk 36 · n 42 · Phase 2 · primary NCT05537571
  • -79.1% vs 2.3% 300 mg Q24W · wk 36 · n 44 · Phase 2 · primary NCT05537571
  • -81.5% vs 1.5% 450 mg Q24W · wk 48 · n 45 · Phase 2 · secondary NCT05537571
  • -76% vs 1.1% 450 mg Q24W · wk 60 · n 45 · Phase 2 · secondary NCT05537571
  • -81.6% vs 1.5% 300 mg Q16W · wk 48 · n 42 · Phase 2 · secondary NCT05537571
  • -77.2% vs 1.5% 300 mg Q24W · wk 48 · n 44 · Phase 2 · secondary NCT05537571
  • -78% vs 1.1% 300 mg Q16W · wk 60 · n 42 · Phase 2 · secondary NCT05537571
  • -70.7% vs 1.1% 300 mg Q24W · wk 60 · n 44 · Phase 2 · secondary NCT05537571

3-point MACE (% with event)

Olpasiran
—Trial running · NCT07293260
Zerlasiran
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Olpasiran: 3 of 4 rows · Zerlasiran: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricOlpasiranZerlasiran
Dropout rate
7.1%225 mg Q12Wa
NCT04270760 · Phase 2
show 22 more results
—225 mg Q12W
NCT04270760 · Phase 2
—225 mg Q12W
NCT04270760 · Phase 2
0%225 mg Q24W
NCT04270760 · Phase 2
—225 mg Q24W
NCT04270760 · Phase 2
—225 mg Q24W
NCT04270760 · Phase 2
5.2%75 mg Q12W
NCT04270760 · Phase 2
—75 mg Q12W
NCT04270760 · Phase 2
—75 mg Q12W
NCT04270760 · Phase 2
1.7%10 mg Q12W
NCT04270760 · Phase 2
—10 mg Q12W
NCT04270760 · Phase 2
—10 mg Q12W
NCT04270760 · Phase 2
16.7%675 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
50%225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
0%225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
66.7%75 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
33.3%75 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
0%30 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
33.3%9 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
11.1%9 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
0%3 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
8.3%High Dose
NCT04987320 · Phase 1 · registry result, not featured evidence
0%Low Dose
NCT04987320 · Phase 1 · registry result, not featured evidence
2.2%450 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
show 2 more results
11.4%300 mg Q16W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
2.3%300 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
Discontinued due to AEs
—225 mg Q12Wa
NCT04270760 · Phase 2
show 22 more results
—225 mg Q12W
NCT04270760 · Phase 2
—225 mg Q12W
NCT04270760 · Phase 2
—225 mg Q24W
NCT04270760 · Phase 2
—225 mg Q24W
NCT04270760 · Phase 2
—225 mg Q24W
NCT04270760 · Phase 2
—75 mg Q12W
NCT04270760 · Phase 2
—75 mg Q12W
NCT04270760 · Phase 2
—75 mg Q12W
NCT04270760 · Phase 2
—10 mg Q12W
NCT04270760 · Phase 2
—10 mg Q12W
NCT04270760 · Phase 2
—10 mg Q12W
NCT04270760 · Phase 2
—675 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
—225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
—225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
—75 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
—75 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
—30 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
—9 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
—9 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
—3 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
—High Dose
NCT04987320 · Phase 1 · registry result, not featured evidence
—Low Dose
NCT04987320 · Phase 1 · registry result, not featured evidence
0%450 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
show 2 more results
4.5%300 mg Q16W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
0%300 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
Serious AEs
—225 mg Q12Wa
NCT04270760 · Phase 2
show 22 more results
11.1%225 mg Q12W
NCT04270760 · Phase 2
10.7%225 mg Q12W
NCT04270760 · Phase 2
—225 mg Q24W
NCT04270760 · Phase 2
9.1%225 mg Q24W
NCT04270760 · Phase 2
7.3%225 mg Q24W
NCT04270760 · Phase 2
—75 mg Q12W
NCT04270760 · Phase 2
3.5%75 mg Q12W
NCT04270760 · Phase 2
5.2%75 mg Q12W
NCT04270760 · Phase 2
—10 mg Q12W
NCT04270760 · Phase 2
7%10 mg Q12W
NCT04270760 · Phase 2
5.2%10 mg Q12W
NCT04270760 · Phase 2
0%675 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
0%225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
0%225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
0%75 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
0%75 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
0%30 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
0%9 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
0%9 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
0%3 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
8.3%High Dose
NCT04987320 · Phase 1 · registry result, not featured evidence
8.3%Low Dose
NCT04987320 · Phase 1 · registry result, not featured evidence
11.1%450 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
show 2 more results
14.3%300 mg Q16W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
4.5%300 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
Most frequent reported AEs
225 mg Q12Wa
covid-19 25.9% (placebo 18.9%)
headache 3.7% (placebo 0%)
immunisation reaction 3.7% (placebo 0%)
NCT04270760 · Phase 2
show 18 more results
225 mg Q12W
back pain 12.5% (placebo 0%)
covid-19 12.5% (placebo 18.9%)
headache 10.7% (placebo 0%)
NCT04270760 · Phase 2
225 mg Q24W
covid-19 18.2% (placebo 18.9%)
fall 3.6% (placebo 0%)
nasopharyngitis 3.6% (placebo 0%)
NCT04270760 · Phase 2
225 mg Q24W
headache 10.9% (placebo 0%)
injection site pain 9.1% (placebo 0%)
covid-19 7.3% (placebo 18.9%)
NCT04270760 · Phase 2
75 mg Q12W
covid-19 19.3% (placebo 18.9%)
urinary tract infection 7% (placebo 0%)
anaemia 3.5% (placebo 1.9%)
NCT04270760 · Phase 2
75 mg Q12W
covid-19 13.8% (placebo 18.9%)
fatigue 13.8% (placebo 1.9%)
headache 12.1% (placebo 0%)
NCT04270760 · Phase 2
10 mg Q12W
covid-19 14% (placebo 18.9%)
back pain 5.3% (placebo 0%)
nasopharyngitis 5.3% (placebo 0%)
NCT04270760 · Phase 2
10 mg Q12W
immunisation reaction 13.8% (placebo 0%)
back pain 10.3% (placebo 0%)
fatigue 10.3% (placebo 1.9%)
NCT04270760 · Phase 2
675 mg
diabetes mellitus 16.7% (placebo 0%)
diastolic hypertension 16.7% (placebo 0%)
dyspnoea 16.7% (placebo 0%)
NCT03626662 · Phase 1 · registry result, not featured evidence
225 mg
abdominal discomfort 0% (placebo 0%)
abdominoplasty 0% (placebo 0%)
actinic keratosis 0% (placebo 0%)
NCT03626662 · Phase 1 · registry result, not featured evidence
225 mg
urinary tract infection 40% (placebo 0%)
abdominal discomfort 20% (placebo 0%)
covid-19 20% (placebo 0%)
NCT03626662 · Phase 1 · registry result, not featured evidence
75 mg
gastrooesophageal reflux disease 16.7% (placebo 0%)
abdominal discomfort 0% (placebo 0%)
abdominoplasty 0% (placebo 0%)
NCT03626662 · Phase 1 · registry result, not featured evidence
75 mg
headache 22.2% (placebo 10%)
actinic keratosis 11.1% (placebo 0%)
arthralgia 11.1% (placebo 0%)
NCT03626662 · Phase 1 · registry result, not featured evidence
30 mg
upper respiratory tract infection 33.3% (placebo 10%)
blood creatine phosphokinase increased 16.7% (placebo 10%)
catheter site pain 16.7% (placebo 0%)
NCT03626662 · Phase 1 · registry result, not featured evidence
9 mg
back pain 16.7% (placebo 10%)
ear injury 16.7% (placebo 0%)
insomnia 16.7% (placebo 0%)
NCT03626662 · Phase 1 · registry result, not featured evidence
9 mg
headache 22.2% (placebo 10%)
upper respiratory tract infection 22.2% (placebo 10%)
animal scratch 11.1% (placebo 0%)
NCT03626662 · Phase 1 · registry result, not featured evidence
3 mg
upper respiratory tract infection 33.3% (placebo 10%)
arthralgia 16.7% (placebo 0%)
contusion 16.7% (placebo 0%)
NCT03626662 · Phase 1 · registry result, not featured evidence
High Dose
covid-19 25%
contusion 16.7%
injection site erythema 16.7%
NCT04987320 · Phase 1 · registry result, not featured evidence
Low Dose
diarrhoea 25%
pyrexia 25%
oropharyngeal pain 16.7%
NCT04987320 · Phase 1 · registry result, not featured evidence
450 mg Q24W
injection site reaction 82.2% (placebo 8.7%)
influenza-like illness 15.6% (placebo 0%)
myalgia 15.6% (placebo 4.3%)
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
show 2 more results
300 mg Q16W
injection site reaction 83.3% (placebo 8.7%)
malaise 14.3% (placebo 0%)
upper respiratory tract infection 14.3% (placebo 4.3%)
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
300 mg Q24W
injection site reaction 81.8% (placebo 8.7%)
upper respiratory tract infection 15.9% (placebo 4.3%)
covid-19 13.6% (placebo 13%)
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Olpasiran

Lp a Change -86.94 vs 9.74 placebo nmol/L @ 0.29wk675 mg
absolute change · nmol/L
NCT03626662 · Phase 1 · registry result, not featured evidence
show 125 more results
-146.718 vs 11.45 placebo nmol/L @ 0.57wk675 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-204.99 vs 0.41 placebo nmol/L @ 1wk675 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-294.89 vs -2.53 placebo nmol/L @ 2.14wk675 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-366.214 vs -1.35 placebo nmol/L @ 4.14wk675 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-351.707 vs -7.72 placebo nmol/L @ 6.14wk675 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-353.207 vs 2.62 placebo nmol/L @ 8.14wk675 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-352.923 vs 2.497 placebo nmol/L @ 12.14wk675 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-276.696 vs 4.697 placebo nmol/L @ 16.14wk675 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-368.258 vs -13.99 placebo nmol/L @ 22.14wk675 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-338.99 vs -20.77 placebo nmol/L @ 26.14wk675 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-320.223 vs -3.902 placebo nmol/L @ 32.14wk675 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-318.725 vs -101.64 placebo nmol/L @ 36.14wk675 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-308.138 vs -96.107 placebo nmol/L @ 40.14wk675 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-299.218 vs -117.353 placebo nmol/L @ 44.14wk675 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-279.478 vs -113.073 placebo nmol/L @ 48.14wk675 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-165.656 vs -81.653 placebo nmol/L @ 52.14wk675 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-6.438 vs 9.74 placebo nmol/L @ 0.29wk225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-88.586 vs 9.74 placebo nmol/L @ 0.29wk225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-13.455 vs 11.45 placebo nmol/L @ 0.57wk225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-116.986 vs 11.45 placebo nmol/L @ 0.57wk225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-69.188 vs 0.41 placebo nmol/L @ 1wk225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-203.215 vs 0.41 placebo nmol/L @ 1wk225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-98.938 vs -2.53 placebo nmol/L @ 2.14wk225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-277.226 vs -2.53 placebo nmol/L @ 2.14wk225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-122.205 vs -6.94 placebo nmol/L @ 2.57wk225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-126.788 vs -3.45 placebo nmol/L @ 3.14wk225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-134.605 vs -1.35 placebo nmol/L @ 4.14wk225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-330.115 vs -1.35 placebo nmol/L @ 4.14wk225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-140.572 vs -7.72 placebo nmol/L @ 6.14wk225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-257.585 vs -7.72 placebo nmol/L @ 6.14wk225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-140.922 vs 2.62 placebo nmol/L @ 8.14wk225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-331.386 vs 2.62 placebo nmol/L @ 8.14wk225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-140.572 vs -0.392 placebo nmol/L @ 10.14wk225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-139.255 vs 2.497 placebo nmol/L @ 12.14wk225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-330.806 vs 2.497 placebo nmol/L @ 12.14wk225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-137.038 vs 4.697 placebo nmol/L @ 16.14wk225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-325.526 vs 4.697 placebo nmol/L @ 16.14wk225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-144.877 vs -13.99 placebo nmol/L @ 22.14wk225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-304.846 vs -13.99 placebo nmol/L @ 22.14wk225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-140.143 vs -20.77 placebo nmol/L @ 26.14wk225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-291.966 vs -20.77 placebo nmol/L @ 26.14wk225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-111.892 vs -3.902 placebo nmol/L @ 32.14wk225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-257.226 vs -3.902 placebo nmol/L @ 32.14wk225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-276.49 vs -101.64 placebo nmol/L @ 36.14wk225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-230.106 vs -96.107 placebo nmol/L @ 40.14wk225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-215.726 vs -117.353 placebo nmol/L @ 44.14wk225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-198.44 vs -113.073 placebo nmol/L @ 48.14wk225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-170.126 vs -81.653 placebo nmol/L @ 52.14wk225 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
1.937 vs 9.74 placebo nmol/L @ 0.29wk75 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-15.119 vs 9.74 placebo nmol/L @ 0.29wk75 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-23.08 vs 11.45 placebo nmol/L @ 0.57wk75 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-49.659 vs 11.45 placebo nmol/L @ 0.57wk75 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-45.863 vs 0.41 placebo nmol/L @ 1wk75 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-102.508 vs 0.41 placebo nmol/L @ 1wk75 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-96.58 vs -2.53 placebo nmol/L @ 2.14wk75 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-208.459 vs -2.53 placebo nmol/L @ 2.14wk75 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-108.463 vs -6.94 placebo nmol/L @ 2.57wk75 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-117.813 vs -3.45 placebo nmol/L @ 3.14wk75 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-124.713 vs -1.35 placebo nmol/L @ 4.14wk75 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-270.641 vs -1.35 placebo nmol/L @ 4.14wk75 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-129.23 vs -7.72 placebo nmol/L @ 6.14wk75 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-282.841 vs -7.72 placebo nmol/L @ 6.14wk75 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-129.513 vs 2.62 placebo nmol/L @ 8.14wk75 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-288.874 vs 2.62 placebo nmol/L @ 8.14wk75 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-128.797 vs -0.392 placebo nmol/L @ 10.14wk75 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-127.98 vs 2.497 placebo nmol/L @ 12.14wk75 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-275.519 vs 2.497 placebo nmol/L @ 12.14wk75 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-123.147 vs 4.697 placebo nmol/L @ 16.14wk75 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-253.641 vs 4.697 placebo nmol/L @ 16.14wk75 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-123.076 vs -13.99 placebo nmol/L @ 22.14wk75 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-195.725 vs -13.99 placebo nmol/L @ 22.14wk75 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-109.435 vs -20.77 placebo nmol/L @ 26.14wk75 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-176.781 vs -20.77 placebo nmol/L @ 26.14wk75 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-104.285 vs -3.902 placebo nmol/L @ 32.14wk75 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-165.297 vs -3.902 placebo nmol/L @ 32.14wk75 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
9.412 vs 9.74 placebo nmol/L @ 0.29wk30 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
3.862 vs 11.45 placebo nmol/L @ 0.57wk30 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-32.272 vs 0.41 placebo nmol/L @ 1wk30 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-63.772 vs -2.53 placebo nmol/L @ 2.14wk30 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-76.222 vs -6.94 placebo nmol/L @ 2.57wk30 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-79.388 vs -3.45 placebo nmol/L @ 3.14wk30 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-86.038 vs -1.35 placebo nmol/L @ 4.14wk30 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-90.072 vs -7.72 placebo nmol/L @ 6.14wk30 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-89.955 vs 2.62 placebo nmol/L @ 8.14wk30 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-88.805 vs -0.392 placebo nmol/L @ 10.14wk30 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-85.072 vs 2.497 placebo nmol/L @ 12.14wk30 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-82.338 vs 4.697 placebo nmol/L @ 16.14wk30 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-63.566 vs -13.99 placebo nmol/L @ 22.14wk30 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-64.1 vs -3.902 placebo nmol/L @ 32.14wk30 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-1.417 vs 9.74 placebo nmol/L @ 0.29wk9 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-4.886 vs 9.74 placebo nmol/L @ 0.29wk9 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-8.317 vs 11.45 placebo nmol/L @ 0.57wk9 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-33.358 vs 11.45 placebo nmol/L @ 0.57wk9 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-35.283 vs 0.41 placebo nmol/L @ 1wk9 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-77.707 vs 0.41 placebo nmol/L @ 1wk9 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-76.094 vs -2.53 placebo nmol/L @ 2.14wk9 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-138.618 vs -2.53 placebo nmol/L @ 2.14wk9 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-85.594 vs -6.94 placebo nmol/L @ 2.57wk9 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-93.714 vs -3.45 placebo nmol/L @ 3.14wk9 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-104.894 vs -1.35 placebo nmol/L @ 4.14wk9 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-188.74 vs -1.35 placebo nmol/L @ 4.14wk9 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-108.734 vs -7.72 placebo nmol/L @ 6.14wk9 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-197.673 vs -7.72 placebo nmol/L @ 6.14wk9 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-106.834 vs 2.62 placebo nmol/L @ 8.14wk9 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-200.251 vs 2.62 placebo nmol/L @ 8.14wk9 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-97.518 vs -0.392 placebo nmol/L @ 10.14wk9 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-96.318 vs 2.497 placebo nmol/L @ 12.14wk9 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-185.407 vs 2.497 placebo nmol/L @ 12.14wk9 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-89.168 vs 4.697 placebo nmol/L @ 16.14wk9 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-162.829 vs 4.697 placebo nmol/L @ 16.14wk9 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-132.696 vs -13.99 placebo nmol/L @ 22.14wk9 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-109.74 vs -20.77 placebo nmol/L @ 26.14wk9 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-85.218 vs -3.902 placebo nmol/L @ 32.14wk9 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-17.82 vs 9.74 placebo nmol/L @ 0.29wk3 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-13.02 vs 11.45 placebo nmol/L @ 0.57wk3 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-24.17 vs 0.41 placebo nmol/L @ 1wk3 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-59.137 vs -2.53 placebo nmol/L @ 2.14wk3 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-71.07 vs -6.94 placebo nmol/L @ 2.57wk3 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-77.853 vs -3.45 placebo nmol/L @ 3.14wk3 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-82.037 vs -1.35 placebo nmol/L @ 4.14wk3 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-89.787 vs -7.72 placebo nmol/L @ 6.14wk3 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-87.22 vs 2.62 placebo nmol/L @ 8.14wk3 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-83.97 vs -0.392 placebo nmol/L @ 10.14wk3 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-73.953 vs 2.497 placebo nmol/L @ 12.14wk3 mg
NCT03626662 · Phase 1 · registry result, not featured evidence
-63.103 vs 4.697 placebo nmol/L @ 16.14wk3 mg
NCT03626662 · Phase 1 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olpasiran's landscape · Zerlasiran's landscape